CD79B (SN8): sc-18902



The Power to Question

BACKGROUND

CD79 (also designated Ig α/lg β) is a heterodimer composed of α chains, designated CD79A or MB-1, and β chains, designated CD79B or B29. The B cell antigen receptor complex (BCR) is formed by the association of CD79 with a membrane immunoglobulin, such as IgM or IgD. The membrane immunoglobulins IgM and IgD achieve surface expression and antigen presentation function in response to CD79 association. The cytoplasmic tails of both CD79A and CD79B contain an ITAM (immuno-receptor tyrosine-based activation) motif, which acts to initiate the Bcr signaling reactions by binding to and activating tyrosine kinases.

REFERENCES

- Poppema, S., et al. 1987. Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. Am. J. Pathol. 127: 418-429.
- van Noesel, C.J., et al. 1991. The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the MB-1 gene. J. Immunol. 146: 3881-3888.
- 3. Mason, D.Y., et al. 1991. The IgM-associated protein MB-1 as a marker of normal and neoplastic B cells. J. Immunol. 147: 2474-2482.
- 4. Ha, H.J., et al. 1992. Molecular cloning and expression pattern of a human gene homologous to the murine MB-1 gene. J. Immunol. 148: 1526-1531.
- Mason, D.Y., et al. 1992. The B29 and MB-1 polypeptides are differentially expressed during human B cell differentiation. Eur. J. Immunol. 22: 2753-2756.
- Jones, M., et al. 1993. Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. J. Immunol. 150: 5429-5435.
- 7. Wood, W.J., Jr., et al. 1993. Isolation and chromosomal mapping of the human immunoglobulin-associated B29 gene (IGB). Genomics 16: 187-192.
- 8. Mason, D.Y., et al. 1995. CD79A: a novel marker for B cell neoplasms in routinely processed tissue samples. Blood 86: 1453-1459.

CHROMOSOMAL LOCATION

Genetic locus: CD79B (human) mapping to 17q23.3.

SOURCE

CD79B (SN8) is a mouse monoclonal antibody raised against cell memebranes from B-prolymphocytic leukemia cells of human origin.

PRODUCT

Each vial contains 200 μg lgG_1 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

CD79B (SN8) is available conjugated to either phycoerythrin (sc-18902 PE) or fluorescein (sc-18902 FITC), 200 µg/ml, for IF, IHC(P) and FCM.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

CD79B (SN8) is recommended for detection of the extracellular portion of CD79B of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 μ g per 1 x 10⁶ cells).

Suitable for use as control antibody for CD79B siRNA (h): sc-35027, CD79B shRNA Plasmid (h): sc-35027-SH and CD79B shRNA (h) Lentiviral Particles: sc-35027-V.


Molecular Weight of CD79B: 39 kDa.

Positive Controls: CD79B (h2): 293T Lysate: sc-115257, U-698-M whole cell lysate: sc-364799 or Ramos cell lysate: sc-2216.


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker $^{\text{TM}}$ Molecular Weight Standards: sc-2035, UltraCruz Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz Mounting Medium: sc-24941 or UltraCruz Hard-set Mounting Medium: sc-359850.

DATA







CD79B (SN8): sc-18902. Western blot analysis of CD79B expression in U-698-M (**A**) and Ramos (**B**) whole cell lysates.

SELECT PRODUCT CITATIONS

- Chu, S.Y., et al. 2008. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Mol. Immunol. 45: 3926-3933.
- Huang, X., et al. 2011. Downregulation of the B-cell receptor signaling component CD79B in plasma cell myeloma: a possible post transcriptional regulation. Pathol. Int. 61: 122-129.

RESEARCH USE

For research use only, not for use in diagnostic procedures.